Spero Therapeutics Inc. – Filings and Transcripts

NASDAQ: SPRO
Share price (11/6/26): $1.03
Market cap (11/6/26): $60.0 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Shelf registration

Registration of securities for employees

Registration of securities for employees

Registration of securities for employees

Ownership Filter

Deshpande Milind

Tregoning Kathleen

News Filter

Change in Directors, Officers or Compensation

Material Definitive Agreement, Other Events, Financial Statements or Exhibits

Announces Second Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-Cd40l Antibody

Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Shareholder Vote Results, Financial Statements or Exhibits

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness